Featured Articles
-
In The UK, Location Is Key To Survival For Life Sciences Startups
2/14/2024
Startup biotech and pharmaceutical companies can benefit from basing themselves in locations where ‘chance’ meetings with decision makers and potential collaborators are more likely to occur. The benefits of proximity between startups and Big Pharma go both ways.
-
How AI Is Helping Drug Developers Help Rare Disease Patients
2/14/2024
BioCryst's chief R&D officer provides examples of how AI and machine learning tools are being used to improve rare disease drug discovery and development.
-
1 In 300 People In The U.S. Is Living With HIV. That’s Not Okay With Jeff Galvin.
2/12/2024
By modifying CD4 T cells using miRNA, Jeff Galvin’s company thinks it can deliver a functional cure for HIV. Here’s the ongoing story of Addimmune and its unique clinical strategy.
-
How To Address ESG Risks Arising From Antimicrobial Resistance
2/12/2024
Pharmaceutical companies must do more to mitigate the growing legal and environmental, social, and governance (ESG) risks around anti-microbial resistance. Experts at international law firm Freshfields offer tips for company leaders.
-
Dynavax’s Evolving Business Model
2/9/2024
Dynavax found a new revenue stream during COVID, and a way to grow market share in the absence of a market. Ryan Spencer describes the ups and downs, and his own journey to CEO role.
-
Where Are They Now? Ono Pharmaceuticals
2/5/2024
Ono Pharmaceuticals continues its quest to become a global biopharmaceutical company, after discovering and helping to launch one of the most successful cancer drugs, Opdivo, in the last decade.
-
The Ozempic Dilemma: What Makes A Dual Brand Approach Viable?
2/5/2024
When should a brand become two brands? Charles River Associates provide analyses and case studies of dual brands to elucidate the pros and cons.
-
Innovation From Animals And Evolution
2/1/2024
Insights gleaned from a variety of animal species, and a deeper understanding of evolution aided by artificial intelligence, could help bring a new wave of therapies to market.
-
Empress Builds Base for Small-Molecule Innovation
2/1/2024
Empress, launched by Flagship Pioneering, aims to harness AI and evolutionary biology to design the next generation of small molecule therapies.
-
Companies to Watch: Promontory Therapeutics
2/1/2024
A novel small molecule developer aims to shake up the solid tumor treatment landscape.